Boston University
Defining the impact of blood cell clycan expression on blood components
Abstract
dc:description.abstractBackground: ABO(H)blood group antigens are expressed on red blood cells (RBCs) and platelets. ABO(H)-incompatible RBC transfusion poses a significant risk for hemolytic transfusion reactions, although in vivo hemolysis can be variable. ABO(H)-incompatible platelet transfusion is generally considered safe; however, post-transfusion count increments can vary. Differences in ABO(H) glycan expression on transfused RBCs/PLTs may influence interactions with recipient anti-A/B antibodies and therefore affect clinical outcomes. Objective: Determine whether ABO glycan expression on platelets correlates with red blood cell expression within individual donors by quantitatively measuring antigen expression using flow cytometry. Methods: Residual blood samples from healthy donors were collected RBCs and platelets isolated by centrifugation. ABH glycan expression was quantified by flow cytometry using anti-A or anti-B antibodies with anti-mouse IgM as the secondary antibody. Median fluorescence intensity (MFI) value was obtained for RBCs and platelets from each individual donor for analysis. Primary antibody concentration was optimized prior to measuring ABH glycan expression on a healthy donor cohort. Statistical analysis (descriptive statistics, coefficient of variation (CV), normality testing, frequency distribution, and Spearman’s rank correlation) was performed using GraphPad Prism. Results: The optimal antibody concentration for maximizing detection of ABO glycans on RBCs while avoiding agglutination was 1:200. Undiluted antibody achieved the best optimal median fluorescence intensity for platelets. ABH glycan expression remained stable through 28 days for RBCs, comparing day 7 vs day 14. ABH glycan expression in platelets only remained stable through 14 days, when comparing day 7 vs day 14. ABH glycan expression in RBCs approximated a Gaussian distribution across individuals, whereas platelet ABH glycan expression demonstrated greater heterogeneity. There was poor/moderate correlation ABH expression between RBCs and PLTs. Individuals with distinct patterns of high/low median fluorescence intensity were observed on platelets compared to a more consistent median fluorescence intensity on RBCs. Conclusions: ABO glycan expression on RBCs and platelets vary widely across individuals with poor correlation between RBCs and platelets within individuals. These findings suggest that ABO(H) glycan expression is regulated by distinct processes in RBCs and PLTs that may influence outcomes following major ABO(H)-incompatible transfusion.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Yean, Aaron
- Advisors dc:contributor.advisor
-
- Herscovitz, Haya
- Stowell, Sean R.
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53798